Alzheimer's disease

Eisai hunts for next Alzheimer’s drug with new research pact
BioPharma Dive
Mon, 04/22/24 - 05:49 pm
Eisai
R&D
Alzheimer's disease
BioArctic
Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation
Xtalks
Thu, 04/18/24 - 10:28 pm
Roche
FDA
Medtech
Eli Lilly
Elecsys pTau217
Alzheimer's disease
diagnostics
Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request
Fierce Biotech
Wed, 04/17/24 - 09:58 pm
Eli Lilly
donanemab
Alzheimer's disease
Leqembi
Biogen
Eisai
FDA
FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test
Pharmaphorum
Thu, 04/11/24 - 10:52 am
diagnostics
Roche
Eli Lilly
Alzheimer's disease
FDA
breakthrough designation
A dementia-focused VC digs past amyloid for new kinds of brain drugs
BioPharma Dive
Wed, 04/3/24 - 11:21 am
funding
venture capital
dementia
Dementia Discovery Fund
Alzheimer's disease
Psychosis: The Other Big Alzheimer’s Therapeutic Target
BioSpace
Tue, 04/2/24 - 11:46 am
Alzheimer's disease
Alzheimer's disease psychosis
Cerevel Therapeutics
Karuna Therapeutics
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
BioSpace
Mon, 04/1/24 - 12:14 pm
Biogen
Eisai
Alzheimer's disease
Leqembi
Aduhelm and an expensive failure to launch
Pharmaphorum
Tue, 03/26/24 - 04:25 pm
Biogen
Alzheimer's disease
Aduhelm
drug launches
Eisai and Biogen facing delay to Leqembi in Europe
Pharmaphorum
Mon, 03/25/24 - 11:22 am
Eisai
Biogen
Leqembi
Europe
Alzheimer's disease
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Roche Plots Neuro Comeback with Promising Mid-Stage Alzheimer’s Data
BioSpace
Tue, 03/12/24 - 11:14 am
Roche
Alzheimer's disease
monoclonal antibodies
Setbacks reset views on highly touted Alzheimer's and ALS drugs
Axios
Mon, 03/11/24 - 05:06 pm
Alzheimer's disease
ALS
Amylyx
Relyvrio
Eli Lilly
donanemab
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
BioSpace
Fri, 03/8/24 - 11:55 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline
Fierce Biotech
Thu, 03/7/24 - 11:38 am
Biogen
Alzheimer's disease
anti-tau antibodies
anti-inflammatory
Eisai
Leqembi
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected
Reuters
Thu, 03/7/24 - 11:07 am
Eisai
Leqembi
drug launches
Alzheimer's disease
Where’s Lilly’s Alzheimer’s approval?
Stat
Tue, 03/5/24 - 11:08 am
Eli Lilly
donanemab
Alzheimer's disease
Vivoryon ‘profoundly disappointed’ by phase 2 Alzheimer’s fail as stock crashes
Fierce Biotech
Mon, 03/4/24 - 11:11 am
Vivoryon
clinical trials
Alzheimer's disease
varoglutamstat
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
Eli Lilly Has More Than an Ozempic Competitor -- Much More
Motley Fool
Wed, 02/21/24 - 11:14 am
Eli Lilly
obesity
cancer
diabetes
psoriasis
Alzheimer's disease
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
BioPharma Dive
Tue, 02/13/24 - 11:16 pm
Biogen
Alzheimer's disease
Leqembi

Pages